ArticleCurrent HIV research2026
Isolated Anti-HBc in People Living with HIV: A 20-Year Experience from Istanbul, Turkey.
Article in Current HIV research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIsolated anti-HBc positivity, defined as the presence of anti-HBc in the absence of HBsAg and anti-HBs, may reflect prior exposure to HBV, occult HBV infection, or a false-positive result. This study aimed to assess the prevalence of isolated anti-HBc positivity and its associated factors among PLWH in Istanbul, Turkey.
methodsThis retrospective cross-sectional study included adult People Living With HIV (PLWH) who underwent HBV serological testing between January 2000 and December 2019 at a tertiary hospital in Istanbul. Demographic and clinical characteristics were analyzed.
resultsAmong 386 PLWH, 8.8% (n = 34) had isolated anti-HBc positivity. Compared with HBV-seronegative PLWH (n = 194), these patients were older (48 (IQR 42-54) vs. 42 (35-50) years; p = 0.007), more likely to have BMI ≥ 25 kg/m² (p = 0.025), and to report smoking (p = 0.041), based on available data. Pre-ART HBV DNA testing was available in 13/34 (38.2%) patients with isolated anti-HBc, and all tested samples were HBV DNA-negative. DISCUSSION: Isolated anti-HBc prevalence was 8.8% in PLWH; older age, BMI ≥25 kg/m², and smoking were more common in this group. Although no HBV DNA was detected in the tested subset, limited HBV DNA testing precluded estimation of OBI prevalence in this cohort.
conclusionRecognition of isolated anti-HBc positivity and occult HBV infection is important for ART selection and patient follow-up. Although isolated anti-HBc positivity was identified in 8.8% of this cohort, more systematic and risk-stratified HBV DNA assessment is needed to better define the true burden of occult HBV infection.
Indexed as
Identifiers
42136229What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.